Search

Boehringer Ingelheim and Yale Clinical and Translational Research Accelerator collaborate to explore potential benefits of digital health technologies for adults with heart failure

BI & Gubra Join Forces to Identify Peptides | Boehringer Ingelheim US

BI & Gubra announce research & licensing agreement focused on the identification & validation of targets & peptide compounds for the treatment of obesity.

Partnering in CardioMetabolic Diseases

Outlook for Partnering in Animal Health 2024

Megan Grether, Head of Business Development & Licensing for Animal Health, shares her perspectives on the year ahead for partnering in Animal Health.

Top-line Phase II Data for treatment of MASH

Boehringer Ingelheim and Zealand Pharma announced top-line Phase II data for treatment of metabolic dysfuntion-associated steatohepatitis (MASH).

First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

Promising Phase II Results in Chronic Kidney Disease

Boehringer Ingelheim announced promising Phase II data for people with chronic kidney disease

Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth

Medicines reach record number of people, net sales rise

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

Currency-adjusted net sales rose by 9.7 percent to 13.5 billion USD.

BI increases commitments to sustainable development

At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development

Financial year 2018

2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic

Fornovo San Giovanni (Bidachem)

Founded in 1981, Fornovo San Giovanni serves both – Human Pharma and Animal Health

BI Cares Signature Program: Empowering Patients to Make Healthy Lifestyle Changes

Signature Program

Results from Phase II MASH trial announced at EASL 2024

Boehringer Ingelheim announced results from Phase II trial in metabolic dysfunction-associated steatohepatitis (MASH) at EASL 2024

Ingelheim

The company headquarters of Boehringer Ingelheim are located in Ingelheim, Germany.

Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline

Boehringer Ingelheim today announced a strong acceleration of its pipeline in 2023, as pivotal trials in key research areas progressed as planned.

Standing together in support of improved access to obesity care

Learn more about how we’re supporting The Obesity Society and their recent consensus statement on obesity to help raise awareness and improve access to care for people living with this chronic medical condition.

First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development

Shanghai

Shanghai serves as an important hub for all of the company’s three business areas: Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing.

Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19

Ordering your medicine online? Find a safe pharmacy first.

Learn what to look for when buying medication and how to verify your pharmacy.

Creating an Inclusive Workplace for Employees with Disabilities

Good business performance gives Boehringer Ingelheim tailwind for investment in R&D

When Passion Starts as a Family Value and Continues as a Work Value

Discover who inspires members of our LatinX Business Resource Group.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers